Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CGON filed to allow the sale of common stock by an affiliate. The filing lists a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ on July 23, 2026, with an aggregate market value of $3,588,620.00. The shares are to be sold for cash and were acquired from the issuer on July 23, 2026 through a stock option exercise. In the preceding three months, a holder identified as Ambaw Bellete sold 52,438 common shares on July 15, 2026 for total proceeds of $3,816,007.65.
CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.
CGON reporting person James Mulay filed to potentially sell common stock through Morgan Stanley Smith Barney, indicating up to 20,237 shares with an aggregate value of $1,483,776.84 as of 07/10/2026. The shares relate to an exercise of stock options for cash and are listed on NASDAQ.
CGON Rule 144 notice reports an intended resale of 3,928 shares via exercise-related sale on 07/01/2026. The notice lists the broker Morgan Stanley Smith Barney LLC and indicates cash as the consideration method. Prior 10b5-1 dispositions by James Mulay are shown: 1,964 shares on 06/15/2026 for $118,075.68 and 15,600 shares on 04/17/2026 for $1,139,024.64.
CG Oncology, Inc. reported an open-market purchase of its Common Stock by Seven Fleet Partners LP, an entity associated with director Brian Guan-Chyun Liu. Seven Fleet Partners LP bought 371,085 shares at $66.87 per share on June 25, 2026, bringing its indirectly reported holdings to 1,886,236 shares.
Liu is the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners LP, and may be deemed to beneficially own these shares. He disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.
CG Oncology director Leonard E. Post reported coordinated stock transactions. On June 24, 2026, he sold 5,000 shares of Common Stock in an open-market transaction at $70.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share. After these moves, he directly owned 5,000 common shares and held 106,077 director stock options expiring on July 8, 2028, indicating an exercise-and-sell pattern with a substantial remaining option position.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the sale of 5,000 shares of Common Stock. The filing lists an Exercise of Stock Options on 06/24/2026 for 5,000 shares to be settled for cash. The filing also discloses recent 10b5-1 executions by Leonard Post: 5,000 shares sold on 06/22/2026 for $325,000 and 1,000 shares sold on 06/04/2026 for $54,500.
CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.